Pramlintide Trial NCT03560960 Now Active, Not Recruiting

As of May 28, 2026, the clinical trial titled "Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease" involving pramlintide has an updated status of active, not recruiting. The study, registered as NCT03560960, is listed at the Early Phase 1 stage. According to the registry entry, this trial is no longer enrolling new participants but continues without new recruitment activity. Pramlintide is an approved compound, and its inclusion here relates to this diagnostic development study rather than a treatment efficacy trial. The registry does not provide results or outcome data at this stage, and no findings have been reported in connection with this status update. No information about trial results, adverse events, or diagnostic performance was included in the available record. This update reflects only the current recruitment and phase status recorded for the trial as of the date given. Readers should note that active, not recruiting indicates the study is ongoing but closed to new participants, consistent with the registry classification. No additional details about study design, sponsor commentary, or timeline changes were provided in the event data. For more background on pramlintide, including its approved uses and general profile, readers can consult the compound overview.